Publications
Download CSV
Download XLSX
Download TXT
Tables
2024 (842)
2023 (887)
2022 (831)
2021 (892)
2020 (640)
2019 (727)
2018 (651)
2017 (681)
2016 (664)
2015 (429)
2014 (376)
2013 (319)
2012 (244)
2011 (163)
2010 (139)
2000 (2)
1977 (2)
All (8489)
Infrastructure Units
Infrastructure Units list
Infrastructure Units table
Researchers
Subset
Documentation
About
Contact
Software
Login
Havervall S
JSON
CSV
XLSX
TXT
Family name
Havervall
Given name
Sebastian
Initials
S
ORCID
ORCID
0000-0003-1671-8183
Affiliations
Division of Internal Medicine Department of Clinical Sciences Karolinska Institutet Danderyd Hospital Stockholm Sweden.
7 publications
PubMed
DOI
Crossref
Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
Bladh O, Greilert-Norin N,
Havervall S
, ...,
Klingström J
, Thålin C
N. Engl. J. Med.
389
(17) 1626-1628 [2023-10-26; online 2023-10-27]
Affinity Proteomics Uppsala [Collaborative]
PubMed
DOI
Crossref
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
Havervall S
, Marking U, Svensson J, ..., Smed-Sörensen A, Thålin C
N. Engl. J. Med.
387
(14) 1333-1336 [2022-10-06; online 2022-09-14]
Affinity Proteomics Uppsala [Collaborative]
Autoimmunity and Serology Profiling [Collaborative]
PubMed
DOI
Crossref
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
Havervall S
, Marking U, Greilert-Norin N, ..., Åberg M, Thålin C
Clin Transl Immunology
11
(4) e1388 [2022-04-18; online 2022-04-18]
Affinity Proteomics Uppsala [Collaborative]
Autoimmunity and Serology Profiling [Collaborative]
PubMed
DOI
Crossref
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking U,
Havervall S
, Greilert-Norin N, ..., Åberg M, Thålin C
Vaccines (Basel)
10
(3) - [2022-02-24; online 2022-02-24]
Affinity Proteomics Uppsala [Collaborative]
Autoimmunity and Serology Profiling [Collaborative]
PubMed
DOI
Crossref
Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.
Havervall S
,
Ng H
,
Jernbom Falk A
, ...,
Hober S
,
Thålin C
J. Intern. Med.
291
(1) 72-80 [2022-01-00; online 2021-09-27]
Affinity Proteomics Uppsala [Service]
Autoimmunity and Serology Profiling [Collaborative]
PubMed
DOI
Crossref
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S
, Marking U, Greilert-Norin N, ..., Åberg M,
Thålin C
EBioMedicine
70
(-) 103523 [2021-08-00; online 2021-08-12]
Affinity Proteomics Uppsala [Collaborative]
Autoimmunity and Serology Profiling [Collaborative]
PubMed
DOI
Crossref
Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.
Hober S
, Hellström C,
Olofsson J
, ...,
Hedhammar M
,
Nilsson P
Clin Transl Immunology
10
(7) e1312 [2021-07-19; online 2021-07-19]
Autoimmunity and Serology Profiling [Technology development]
SciLifeLab Data Centre
Publications
9.5.1